Loading…
for educational and safety purposes
Mescaline and Escaline both come up in the same conversations; they overlap on Serotonin. Mescaline: Mescaline (3,4,5-trimethoxyphenethylamine) is a naturally occurring psychedelic alkaloid and the prototypical phenethylamine hallucinogen, isolated in 1897 from the peyote cactus (Lophophora williamsii) and also present in South American columnar cacti such as the San Pedro or wachuma (Trichocereus species). Escaline: Escaline is a psychedelic phenethylamine of the mescaline-analog scaline family, corresponding to mescaline with an ethoxy group replacing the 4-position methoxy.
Mescaline (3,4,5-trimethoxyphenethylamine) is a naturally occurring psychedelic alkaloid and the prototypical phenethylamine hallucinogen, isolated in 1897 from the peyote cactus (Lophophora williamsii) and also present in South American columnar cacti such as the San Pedro or wachuma (Trichocereus species). Archaeological evidence indicates ritual use of mescaline-bearing cacti for more than 6000 years, making it one of the oldest documented psychoactive substances. Its characteristic alterations of perception, mood, and cognition are attributed principally to agonist activity at the serotonin 5-HT2A receptor, though it binds within a similar concentration range to 5-HT2C and 5-HT1A sites. Compared with other classic psychedelics it has notably low potency, requiring gram-scale oral doses, and it is largely excreted unchanged in the urine. Renewed scientific interest in psychedelic therapeutics has returned mescaline to controlled human study after decades of neglect.
Escaline is a psychedelic phenethylamine of the mescaline-analog scaline family, corresponding to mescaline with an ethoxy group replacing the 4-position methoxy. Like its parent it acts principally through agonism at serotonin 5-HT2A receptors, producing a mescaline-like state often described as clear and warm but with substantially greater potency by weight. Systematic head-twitch studies in mice have confirmed that homologation of the 4-alkoxy substituent, from methoxy to ethoxy or propoxy, increases 5-HT2A-mediated potency, mirroring the human potency relationships reported by Shulgin. Structural comparisons within fluorinated analogs further illustrate how modification at this position modulates activity and duration. Escaline remains only lightly studied, and detailed human safety and pharmacokinetic data are lacking.
both fingerprints on one instrument; where the marks line up the two compounds work the same lever, where a slot goes dark only one of them touches it. read straight from each entry's affinity table; nothing here is invented.
agonist
agonist
agonist
agonist
weak binding
agonist
strengths are the entries' qualitative ratings (strong / moderate / weak); Ki and EC50 figures appear where an entry records them.